News | Page 3

Daily news and information for physicians in a range of specialties and practice settings.
Data revealed a response rate of 29% for those on the therapy compared to 2% with placebo, with median platelet counts at 24 weeks of 95,000/µL in the SR group, 49,000/µL in the IR group, and 20,500/µL in the non-responders.
Teens who self-reported inattention, hyperactivity/impulsivity, and conduct disorder also reported higher risky driving behaviors.
Clostridium difficile could be mutating to transfer from pets to humans.
 
Patients using statins had a 4.3% infection rate compared with a 7.8% rate for those not taking statins, concluding that statins may be associated with a 20% risk reduction. 
Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.
Burosumab is the first FDA approved treatment for this rare, hereditary disorder that affects 3000 children and 12,000 adults in the US.
The disparity of fast food swamps significantly affecting pediatric patients with T1D but not those with T2D came as a surprise to researchers.
SGLT-2 inhibitors and GLP-1 agonists were associated with 1% and 0.6% reductions in all-cause mortality, respectively.
Treatment now offers an individualized approach to control bleeding in appropriate patients undergoing surgery.
The therapy, when used prophylactically either weekly or biweekly, showed a statistically significant reduction in treated bleeds in comparison to no prophylaxis.
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.
$loginModal$